Studies investigating what is damaging the kidney in lupus nephritis point to tubulointerstitial inflammation as an important risk factor. Tubulointerstitial inflammation in patients with lupus ...

Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

DESTIN, Fla. — Despite new therapies and evolving research, lupus nephritis continues to present clinical and research challenges, according to a presenter at the Congress of Clinical Rheumatology ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Please provide your email address to receive an email when new articles are posted on . New advancements in lupus nephritis treatment are forcing both nephrologists and rheumatologists to keep pace ...

Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment. Payers consider clinical outcomes, cost, and value when ...

Gazyva (obinutuzumab) is a lab-made antibody medication used for treating certain blood cancers. The FDA recently approved the combined use of Gazyva and standard therapy in adults having an active ...